Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, discuss the use of biosimilars at their organizations and what payers should be thinking about when considering biosimilar transitions.
EP. 1: Optimizing Transitions to Biosimilars
Ryan Haumschild, PharmD, MS, MBA, discusses optimizing the transition to biosimilars, covering from what patients to look for as candidates to the process of switching a patient from a brand to a biosimilar to the importance of patient education.
EP. 2: Optimizing Transitions to Biosimilars Continued
Ryan Haumschild, PharmD, MS, MBA, continues focusing on transition optimization, explaining how to efficiently create your inventory, how his use of biosimilars will change in the future, and offering advice to those looking to transition to biosimilars.
EP. 3: Increased Use of Biosimilars
Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, discuss the increased use of biosimilars, including successes and challenges and the process of transitioning to biosimilars at their organizations.
EP. 4: Transitioning to a Biosimilar Program
Two experts examine how the biosimilar programs at their organization were created and the initial goals they had in mind.
EP. 5: Protocols and Laws for Transitioning to Biosimilars
Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, recall what protocols and laws their organizations needed to abide by when transitioning to their biosimilars programs.
EP. 6: Tracking Usage and Monitoring the Impact of Biosimilars
Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, discuss tracking their use of biosimilar by their providers and outcome measures they utilize to monitor biosimilars.
EP. 7: Integrating Biosimilars for HCPs, into Electronic Health Records, and in Clinical Pathways/Care Plans
Two experts explain if they had to create any incentives for health care providers to prescribe biosimilars, whether they encountered challenges with their electronic health records, and if their biosimilar programs impacted their clinical pathway/care plans.
EP. 8: Evaluating Biosimilar Programs and Formularies
Kathy Oubre, MS, closes this Insights program by evaluating her organization’s biosimilars program and formularies, including third party preference on the use of specific biosimilars and whether biosimilars can be used outside of their indications.
2 Clarke Drive Cranbury, NJ 08512